Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721884 · ClinicalTrials.gov registry record · Phase 1
Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
A Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO), sponsored by National University of Natural Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06721884 is a Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO) that is actively recruiting participants, run by National University of Natural Medicine. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06721884, a Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO), is actively recruiting participants, sponsored by National University of Natural Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. This study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests. The trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods. This study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT Artemisia Annua Leaf
Study Locations (1)
Oregon
- Helfgott Research Institute - National University of Natural Medicine - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721884
The ClinicalTrials.gov registry entry for NCT06721884 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National University of Natural Medicine, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Intestinal Bacterial Overgrowth Syndrome (SIBO) appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06721884 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT06721884 about?
NCT06721884 is a clinical study titled "Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth". Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address thi...
What is the current status of trial NCT06721884?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-01-01. Estimated completion is 2026-01.
What conditions does trial NCT06721884 study?
This clinical trial studies the following conditions: Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
What interventions are being tested in trial NCT06721884?
The interventions under investigation include: placebo (OTHER), Artemisia Annua Leaf (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06721884?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721884 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.